June 15th, 2024
The ChondrosarcomaFoundation was the first foundation to be inducted into the NORD IAMRARE Patient Registry 2.0 platform and the 44th Foundation to have a Patient Registry in the platform itself. In February 2023, we had a soft launch with a few…
Read ArticleJune 8th, 2024
The Chondrosarcoma Foundation was the first foundation to be inducted into the NORD IAMRARE Patient Registry 2.0 platform and the 44th Foundation to have a Patient Registry in the platform itself. We were approved by NorthStar IRB in early February…
Read ArticleMay 13th, 2024
The Chondrosarcoma (CS) Foundation will commemorate its fourth anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and will report on a global natural history study.
On May 14,…
May 2nd, 2024
Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells
Jian Song1, Xiaobo Wang2, Jiaxue Zhu3, Jun Liu4 1Department of Orthopaedics, Shandong Jining No.1 People’s Hospital, Jining, Shandong, 272000, China;…
Read ArticleApril 24th, 2024
Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his…
Read ArticleRyan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…
Read ArticleRyan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,…
Read ArticleApril 22nd, 2024
Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a…
Read ArticleApril 4th, 2024
Abstract
This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal…
March 26th, 2024
Metastatic mesenchymal chondrosarcoma showing a sustained response to cabozantinib: A case report Veronika Blum, 1 , † Vanghelita Andrei, 2 , † Baptiste Ameline, 2 Silvia Hofer, 3 Bruno Fuchs, 1 Klaus Strobel, 1 Anna Allemann, 1 Beata Bode, 4…
Read Article